Olsalazine

Olsalazine
Clinical data
Trade names	Dipentum
AHFS/Drugs.com	Monograph
MedlinePlus	a601088
License data	US DailyMed: Olsalazine;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	A07EC03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	99%
Elimination half-life	0.9 hours
Identifiers
CAS Number	15722-48-2 ;
PubChem CID	22419;
DrugBank	DB01250 ;
ChemSpider	10642377 ;
UNII	ULS5I8J03O;
KEGG	D08295 ; as salt: D00727 ;
ChEMBL	ChEMBL425 ;
CompTox Dashboard (EPA)	DTXSID8023391 ;
ECHA InfoCard	100.116.494
Chemical and physical data
Formula	C14H10N2O6
Molar mass	302.242 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2;
	InChI InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ ; Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N ;
	(what is this?) (verify)

Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. It is sold under the brand name Dipentum.

Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.